Xin Shelley Wang, MD
MD Anderson Cancer Center
Houston, Texas, USA
Prevalence of high symptom burden and its impact on functioning and quality of life in patients with multiple myeloma 3-9 months following autologous transplant
Although multiple myeloma (MM) patients are expected to have lower disease burden post autologous hematopoietic stem cell transplantation (AuSCT), symptom burden and its impact on patient's quality of life (QoL) have not been prospectively studied in this time period, when maintenance therapy may be implemented.
Visit our website at: http://www.myeloma.org